Pegcetacoplan Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools neutral scientific reference catalog

Complement inhibitor; compstatin-derived PEGylated peptide compound Reference needs_revision Best effort · source review pending

Also known as: APL-2, APL 2, Empaveli, Aspaveli, Syfovre

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Components

Two identical compstatin-derived cyclic pentadecapeptides + Linear 40 kDa polyethylene glycol (PEG) linker

Storage

For the marketed subcutaneous solution, labeling specifies refrigerated storage at 2–8 °C in the original carton to protect from light. This is product-specific storage information, not a general stability specification for all pegcetacoplan preparations.

Blend Components

This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.

Component

Two identical compstatin-derived cyclic pentadecapeptides

Calculator Profile

Component

Linear 40 kDa polyethylene glycol (PEG) linker

Calculator Profile

Open All in Blend Calculator

Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.

Best-Effort Research Profile

Pegcetacoplan is a symmetrical biologic molecule consisting of two identical compstatin-derived pentadeptides covalently linked to the ends of a linear 40 kDa PEG molecule. It binds complement component C3 and C3b, inhibiting complement activation and downstream complement-mediated processes. The reported molecular weight is approximately 43.5 kDa, and the labeled molecular formula is C1970H3848N50O947S4.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Median effective half-life of approximately 8.6 days in patients with paroxysmal nocturnal hemoglobinuria. Following intravitreal administration, reported population pharmacokinetic estimates include an absorption half-life of approximately 13.1 days and an elimination half-life of approximately 4.51 days.

Administration Routes (Research)

SubcutaneousIntravitreal

Reported Research Effects

Inhibits complement component C3 and C3b activity
Suppresses complement activation and downstream complement-mediated inflammation
Reduces complement-mediated hemolysis in paroxysmal nocturnal hemoglobinuria models and clinical use

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

Pegcetacoplan has been developed and authorized in multiple complement-mediated disease settings, including paroxysmal nocturnal hemoglobinuria, geographic atrophy secondary to age-related macular degeneration, C3 glomerulopathy, and primary immune-complex membranoproliferative glomerulonephritis. Indications and formulations are route- and jurisdiction-specific.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

CAS RN: 2019171-69-6; FDA UNII: TO3JYR3BOU; ATC: L04AJ03; ophthalmological ATC: S01XA31; molecular formula: C1970H3848N50O947S4; approximate molecular weight: 43.5 kDa

Source-Backed Observations

Pegcetacoplan is a peptide-PEG conjugate rather than a conventional small molecule. PubChem notes that it may not correspond to a discrete small-molecule structure. Product labeling describes the marketed formulations as sterile aqueous solutions; formulation-specific concentration and storage information should not be interpreted as intrinsic properties of the unconstrained compound.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

EMPAVELI (pegcetacoplan) Prescribing Information, revised July 2025
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215014s011lbl.pdf (accessed 2026-08-28)

SYFOVRE (pegcetacoplan) Prescribing Information, revised December 2024
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217171s002lbl.pdf (accessed 2026-08-28)

Aspaveli: European Public Assessment Report
https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli (accessed 2026-08-28)

Pegcetacoplan - PubChem Compound Summary
https://pubchem.ncbi.nlm.nih.gov/compound/Pegcetacoplan (accessed 2026-08-28)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria
https://pubmed.ncbi.nlm.nih.gov/39612158/ (accessed 2026-08-28)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Blend CalculatorPre-filled with all blend components Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.